bioskin® Announces Participation in the 6th AGAH Dermatological Product Development Workshop in June in London
HAMBURG, Germany, May 8, 2015 /PRNewswire/ -- bioskin® is excited to announce its participation in the 6th AGAH Dermatological Product Development Workshop. This 2-day workshop will be held June 23 - 24, 2015 at The Cumberland Hotel in London, UK.
This International Workshop on Bridging Strategies from Early Development to Regulatory Approval brings together experts in topical drug development from industry, academics and agencies. Many of the key issues and challenges involved in the successful development of dermatological products will be addressed. Practical and effective approaches to topical drug development will be covered focusing on
- Building confidence towards selection of clinical candidate using tool kit approach
- Risk mitigation strategies
- Indication-specific development strategies
- Regulatory perspectives from both sides of the pond
"The workshop is intended for all of those interested in the development of dermatologicals, whether these are NCEs, innovative formulations or generic drug products. There will be ample opportunity for networking and hands-on discussions," said Walter Wigger-Alberti, CEO of bioskin®.
bioskin® is a sponsor of the event and is actively participating on the scientific and organizing committees. Betsy Hughes-Formella, an Executive Director from bioskin®, will moderate a session on approaches and risk mitigation in the clinical development of innovative and generic products.
Speakers and moderators are: Karl R. Beutner, MD, PhD, Rogne Bioscience Inc., USA, Charles Bon, MS, Biostudy Solutions, LLC, USA, Professor Marc Brown, MedPharm, UK, Ian Claydon, Regulatory Consultant, UK, Professor Richard Guy, University of Bath, UK, Hans Hofland, PhD, Dermira, USA, Edward Hsia, PhD, Allergan, USA, Betsy Hughes-Formella, PhD, bioskin GmbH, Germany, Isadore Kanfer, PhD, CRO Consulting, South Africa, Jon Lenn, Stiefel, a GSK company, USA, Richard Lloyd, GlaxoSmithKline, UK, Vijendra Nalamothu, PhD, Tergus Pharma, USA, Barry T. Peterson, PhD, Philips Healthcare, USA, Karsten Petersson, LEO Pharma, Denmark, Christoph Riethmuller, PhD, Serendip GmbH, Germany, Mads Almose Ropke, PhD, LEO Pharma, Denmark, Leandro Santos, Stiefel, a GSK company, USA, John M. Sall, PharmD, PhD, Stiefel, a GSK company, USA, Frank Sinner, PhD, Joanneum Research, Austria, Pieter Spee, PhD MSc Ing, FibroTx LLC, Estonia, Quan Yang, PhD, MPharm, MHRA, UK.
To view the program and register please visit www.csioffice.de/derma2015.
About AGAH
The Association for Applied Human Pharmacology (AGAH) is a scientifically and medically oriented non-profit organization which focuses on work in the field of explorative drug development and human pharmacology. The organization is especially a forum for professionals who work in the field of translational medicine, i.e. bringing new medicinal products from the bench into clinical research.
About bioskin®
Founded in 1992, bioskin® provides extensive experience in innovative trial design, Phase I & Proof-of-Concept trials, and global Phase II, III and IV trials, making bioskin® a unique and respected partner in dermatology research services. bioskin® has offices in Hamburg, Germany and Wilmington NC, USA.
Other upcoming events
Meet with bioskin representatives at the World Congress of Dermatology, June 8 - 12, 2015 in Vancouver, Canada and the DIA Annual Meeting, June 14 - 17, 2015 in Washington, DC.
Media Contact:
Ilka Schmeichel
+494060689712
SOURCE bioskin
Share this article